Acorda Therapeutics (ACOR) Release: First Study of Diazepam Nasal Spray in People With Epilepsy Shows Feasibility of Dosing During Seizure
6/26/2013 10:01:08 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced results of the first clinical study to assess pharmacokinetics, safety and tolerability of Diazepam Nasal Spray in people with epilepsy. Study findings were presented on June 25 at the biennial International Congress of the International League Against Epilepsy (ILAE) and International Bureau for Epilepsy (IBE), being held in Montreal, Canada. Diazepam Nasal Spray is being developed for the treatment of people with epilepsy who experience cluster seizures, also known as acute repetitive seizures.
Help employers find you! Check out all the jobs and post your resume.
comments powered by